摘要
艾拉莫德作为一种新型免疫抑制剂,可通过抑制炎症细胞增殖和减少炎症细胞因子释放的方式介导抗炎信号通路,发挥抗炎作用;可通过影响免疫细胞增殖及免疫因子表达,减少机体免疫复合物的产生及沉积,发挥调节免疫作用;可通过介导Wnt/β-连环蛋白、Toll样受体4/核因子κB和护骨因子/核因子κB受体活化因子配体等信号通路调节骨代谢,发挥骨保护作用;可通过抑制转化生长因子β1/Smad2/3信号通路及肿瘤坏死因子α、白细胞介素1、白细胞介素6和基质金属蛋白酶9等炎症细胞因子在肺组织的表达并抑制胶原蛋白及纤连蛋白的表达,发挥抑制肺纤维化作用。其疗效及安全性在类风湿性关节炎和原发性干燥综合征的临床应用中已得到肯定并纳入了疾病的诊疗规范中;其在系统性红斑狼疮和强直性脊柱炎等其他结缔组织病的临床应用过程中同样表现出良好的疗效,且尚未发现明显的安全隐患。
As a new type of immunosuppressant,iguratimod can mediate the anti-inflammatory signaling pathway by inhibiting the proliferation of inflammatory cells and reducing the release of inflammatory cytokines,and play the role of anti-inflammatory.It can affect the proliferation of immune cells and the expression of immune factors,reduce the production and deposition of immune complexes in the body,and play the role of immune regulation.It can regulate bone metabolism by mediating signaling pathways such as Wnt/β-catenin,Toll-like receptor 4/nuclear factor-κB and osteoprotegerin/nuclear factor-κB receptor activating factor ligand,and play a role in bone protection.It can inhibit pulmonary fibrosis by inhibiting the expression of transforming growth factorβ1/Smad2/3 signaling pathway,tumor necrosis factor-α,interleukin-1,interleukin-6,matrix metalloproteinase-9 and other inflammatory cytokines in lung tissue,and inhibiting the expression of collagen and fibronectin.Its efficacy and safety have been confirmed in the clinical application of rheumatoid arthritis and primary Sjogren syndrome and included in the diagnosis and treatment of the disease.It has also shown good efficacy in the clinical application of other connective tissue diseases such as systemic lupus erythematosus and ankylosing spondylitis,and no obvious safety risks have been found.
作者
杨晓蓉
周淑红
郭莉江
陈英
冀盈盈
许丽洁
YANG Xiaorong;ZHOU Shuhong;GUO Lijiang;CHEN Ying;JI Yingying;XU Lijie(The First School of Clinical Medicine,Gansu University of Chinese Medicine,Lanzhou 730030,China;Dept.of Integrated Traditional Chinese and Western Medical Rheumatology&Immunology,Gansu Provincial Hospital,Lanzhou 730030,China)
出处
《中国药房》
CAS
北大核心
2024年第5期629-634,共6页
China Pharmacy
基金
甘肃省人民医院国家级科研项目培育计划一般项目(No.19SYPYB-23)
甘肃省人民医院院内科研基金项目(No.22GSSYD-79)。
关键词
艾拉莫德
结缔组织病
作用机制
临床应用
iguratimod
connective tissue disease
mechanism of action
clinical application
